A Study of LY3405105 in Participants With Advanced Cancer

Status:	Recruiting
Conditions:	Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	4/5/2019
Start Date:	January 25, 2019
End Date:	May 5, 2022
Contact:	There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Email:	clinicaltrials.gov@lilly.com
Phone:	1-317-615-4559

A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors

The main purpose of this study is to investigate the safety of LY3405105 in participants with
advanced cancer. The study has two parts (A and B). Participants will only enroll in one
part.

Inclusion Criteria:

- Have histological or cytological evidence of a diagnosis of a solid tumor cancer that
is advanced and/or metastatic

- Have available archived tissue for exploratory biomarker analysis

- Have adequate organ function

- Have discontinued all previous treatments for cancer and recovered from their side
effects

- Are able to swallow capsules/tablets

Exclusion Criteria:

- Have symptomatic central nervous system (CNS) malignancy or metastasis

- Have symptomatic human immunodeficiency virus (HIV), Hepatitis A, B, or C

- Have congestive heart failure

- Are breastfeeding

We found this trial at

sites

Princess Margaret Hospital

Toronto, Ontario

Principal Investigator: Phillippe Bedard

Phone: 4169464534

from

Toronto,